An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
Status:
Completed
Trial end date:
2019-06-28
Target enrollment:
Participant gender:
Summary
This study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose
(RP2D) of humanized anti-EGFR monoclonal antibody, HLX07, in patients with epithelial cancer
who have failed standard therapy and deemed unamenable by conventional therapy. This study
will also evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor
effect of HLX07 and explore the potential prognostic and predictive biomarkers.